Clinical Trials Using Gefitinib

Clinical trials are research studies that involve people. The clinical trials on this list are studying Gefitinib. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-5 of 5
  • Osimertinib and Gefitinib in Treating Patients with EGFR Mutant Stage IV Non-small Cell Lung cancer

    This randomized phase I / II trial studies the side effects and best dose of osimertinib when given together with gefitinib in treating patients with EGFR mutant stage IV non-small cell lung cancer. Osimertinib and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

    Background: Advanced urothelial cancer has no cure. But only a few chemotherapy drugs have been tested for it. The Co-eXpression ExtrapolatioN (COXEN) model predicts if cells respond to treatment. It may also help determine which drugs fight urothelial cancer based on the characteristics of a tumor. Researchers want to test if this model can choose the best therapy for advanced urothelial cancer within 3 weeks and how tumors respond to the next best therapy. Objective: To test if the COXEN model can choose the best therapy for advanced urothelial cancer within 3 weeks. Eligibility: People ages 18 and older whose urothelial cancer has spread after at least 1 line of chemotherapy Design: Participants will be screened with medical history, physical exam, blood and urine tests, and tumor scans. Participants will provide a tumor sample from a previous surgery and a new biopsy. A needle will remove a small piece of tumor. Participants will repeat screening tests, plus have an EKG and scan. For the scan, they will get an injection of radioactive drug. They will lie in a machine that takes pictures. Participants will take the drugs assigned by the COXEN model. They will have visits every 2 3 weeks. These will include blood and urine tests. Participants will have tumor scans every 8 9 weeks. Participants may have another biopsy. Participants will take the drugs until they can t tolerate the side effects or their cancer worsens. They may be assigned to a second COXEN therapy. Participants will have a follow-up visit 4 5 weeks after their last drug dose. Participants will be contacted by phone every few months until death. ...
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • Gefitinib in Treating Patients With Newly Diagnosed Liver Cancer That Can Be Removed By Surgery

    This pilot early phase I trial studies gefitinib in treating patients with newly diagnosed liver cancer that can be removed by surgery. Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland

  • Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

    Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.
    Location: 4 locations

  • Nazartinib and Gefitinib in Treating Patients with Recurrent or Stage IIIB-IV EGFR-Mutant Non-small Cell Lung Cancer

    This phase II trial studies how well nazartinib and gefitinib work in treating patients with EGFR-mutant non-small cell lung cancer that has come back or is stage IIIB-IV. Nazartinib and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts